Second-generation SERM (benzothiophene)
A benzothiophene SERM; an osteoporosis drug with breast cancer prevention activity but no uterine partial agonism, distinguishing it from tamoxifen.
Abstract
Raloxifene ([6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone; CAS 84449-90-1; molecular formula C28H27NO4S; molecular weight 473.58) is a benzothiophene second-generation SERM developed at Eli Lilly and approved by the FDA in 1997 under the trade name Evista. Distinct from tamoxifen by tissue selectivity profile: ER antagonism in breast and uterus, partial agonism in bone and liver. The absence of uterine partial agonism eliminates the endometrial cancer risk seen with tamoxifen and is the principal distinguishing clinical feature. Plasma half-life is approximately 27 hours; metabolism is via glucuronidation. Approved for postmenopausal osteoporosis treatment and prevention, and for breast cancer risk reduction in postmenopausal women at high risk. The MORE and STAR trials established the breast cancer prevention activity. Adverse events include thromboembolism (similar to tamoxifen), hot flashes, and leg cramps. Used as the canonical second-generation SERM with bone-selective profile.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.